Abstract:When SARS‐CoV‐2 enters inside the cell by fusion process it encodes few proteins including main protease with the help of cellular ribosomes. This main protease mediates the maturation cleavage of polyproteins at 11 different regions, which is a notable step in virus's life cycle. SARS‐CoV‐2 Mpro is mainly a homo‐dimeric enzyme consisting of three domains. The large substrate‐binding site with a catalytic dyad of His41 and Cys145 is located between chymotrypsin‐like domains I and picornavirus 3C protease‐like domain II. Inhibition of this substrate binding site disrupt the replication process. But being large substrate‐binding site, peptide is more suitable than small molecules for inhibiting this crucial site. The outcome of this computational study displays that the attachment of peptide with Mpro protease can be a good strategy to inhibit the substrate‐binding site which may lead to disruption of replication process of SARS CoV‐2. The COVID‐19 pandemic has been a public health emergency, with deadly forms constantly emerging around the world, highlighting the dire need for highly effective antiviral therapeutics. Peptide therapeutics show significant potential for this viral disease due to their efficiency, safety, and specificity. Here, two thousand seven hundred eight antibacterial peptides were screened computationally targeting the Main protease (Mpro) of SARS CoV‐2. Six top‐ranked peptides according to their binding scores, binding pose were investigated by molecular dynamics to explore the interaction and binding behavior of peptide‐Mpro complexes. The structural and energetic characteristics of Mpro‐DRAMP01760 and Mpro‐DRAMP01808 complexes fluctuated less during a 250 ns MD simulation. In addition, three peptides (DRAMP01760, DRAMP01808, and DRAMP01342) bind strongly to Mpro protein, according to the free energy landscape and principal component analysis. Peptide helicity and secondary structure analysis are in agreement with our findings. Interaction analysis of protein‐peptide complexes demonstrated that Mpro's residue CYS145, HIS41, PRO168, GLU166, GLN189, ASN142, MET49, and THR26 play significant contributions in peptide‐protein attachment. Binding free energy analysis (MM‐PBSA) demonstrated the energy profile of interacting residues of Mpro in peptide‐Mpro complexes. To summarize, the peptides DRAMP01808 and DRAMP01760 may be highly Mpro specific, resulting disruption in a viral replication and transcription. The results of this research are expected to assist future research toward the development of antiviral peptide‐based therapeutics for Covid‐19 treatment.

Dual-targeting Cyclic Peptides of Receptor-Binding Domain (RBD) and Main Protease (mpro) As Potential Drug Leads for the Treatment of SARS-CoV-2 Infection

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Discovery of Dual S-RBD/NRP1-targeting Peptides: Structure-Based Virtual Screening, Synthesis, Biological Evaluation, and Molecular Dynamics Simulation Studies

Structure-Based Discovery of Novel Nonpeptide Inhibitors Targeting SARS-CoV-2 M<SUP>pro</SUP>

Molecular Modelling, Synthesis, and In-Vitro Assay to Identify Potential Antiviral Peptides Targeting the 3-Chymotrypsin-Like Protease of SARS-CoV-2

Large scale peptide screening against main protease of SARS CoV‐2

Exploiting Hydrophobic Amino Acid Scanning to Develop Cyclic Peptide Inhibitors of the SARS‐CoV‐2 Main Protease with Antiviral Activity

High-throughput Screening and Experimental Identification of Potent Drugs Targeting SARS-CoV-2 Main Protease

Dual Inhibitors of Main Protease (MPro) and Cathepsin L as Potent Antivirals against SARS-CoV2

Discovery of potential inhibitors targeting SARS-CoV-2 Mpro

Non-covalent Cyclic Peptides Simultaneously Targeting Mpro and NRP1 Are Highly Effective Against Omicron BA.2.75

In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations.

Bionics Design of Affinity Peptide Inhibitors for SARS-CoV-2 RBD to Block SARS-CoV-2 RBD-ACE2 Interactions

Discovery of Potential SARS-CoV-2M Protease Inhibitors by Virtual Screening, Molecular Dynamics, and Binding Free Energy Analyses

Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease

Potential Inhibitors for Targeting Mpro and Spike of SARS-CoV-2 Based on Sequence and Structural Pharmacology Analysis

Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease

Design of SARS-CoV-2 Mpro, PLpro dual-target inhibitors based on deep reinforcement learning and virtual screening

Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors

De Novo Discovery of a Noncovalent Cell-Penetrating Bicyclic Peptide Inhibitor Targeting SARS-CoV-2 Main Protease

Peptide inhibitors derived from the nsp7 and nsp8 cofactors of nsp12 targeting different substrate binding sites of nsp12 of the SARS-CoV-2